Lupin has allotted 36979 fully paid-up equity shares of Rs 2/- each. These shares have been allotted upon exercising of vested options granted to the employees under Stock Option plans of the Company.In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,24,69,084 consisting of 45,62,34,542 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Lupin announced today the acquisition of anti-diabetes trademarks GIBTULIO�, GIBTULIO MET� and AJADUO� from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO� and GIBTULIO MET� since 2016, and AJADUO� since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. GIBTULIO� (empagliflozin), GIBTULIO MET� (empagliflozin + metformin) and AJADUO� (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.Powered by Capital Market - Live News

Lupin allots 2642 equity shares under ESOP on 19 November 2024. In view of the above, the issued and paid-up share capital of the Company has been increased to Rs 91,23,95,126 consisting of 45,61,97,563 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Net profit of Lupin rose 74.12% to Rs 852.63 crore in the quarter ended September 2024 as against Rs 489.67 crore during the previous quarter ended September 2023. Sales rose 11.29% to Rs 5497.01 crore in the quarter ended September 2024 as against Rs 4939.23 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5497.014939.23 11 OPM %24.3818.58 - PBDT1311.78877.52 49 PBT1054.86629.67 68 NP852.63489.67 74 Powered by Capital Market - Live News

Lupin has allotted 51,609 equity shares under ESOP on 23 October 2024. The issued and paid-up capital of the Company has been increased to Rs 91,23,89,842 consisting of 45,61,94,921 equity shares of Rs 2/- each.Powered by Capital Market - Live News